… Kunz, professor of Internal Medicine (Medical Oncology) and director of … usually in pill form. Examples include everolimus, Sutent (sunitinib), and … several new FDA-approved treatments and clinical trials in their … is growing. We want doctors to be more aware …

… to cabozantinib vs sunitinib [Sutent] and cabozantinib was superior … and the FDA approved having the clinical trial data added … seen in other trials. These were the treatment-related adverse events … sunitinib in first-line treatment of advanced renal cell …

… PEAK phase 3 trial evaluating bezuclastinib plus Sutent (sunitinib) … to submit a New Drug Application in 2026. … imatinib revolutionized first-line treatment, resistance inevitably develops, … combination may shift the treatment paradigm, offering patients not …

… GIST), treatment with bezuclastinib (CGT9486) in combination with Sutent (sunitinib … S. Food and Drug Administration (FDA) in the … PEAK trial compared bezuclastinib plus Sutent against Sutent alone … Sarcoma Medical Oncology, Division of Cancer Medicine, The …

… from Benzinga Pro. The biotechnology company focused on precision … trial of bezuclastinib plus Pfizer Inc.’s (NYSE:PFE) Sutent … estimated mean duration of treatment for the bezuclastinib combination … .S. Food and Drug Administration (FDA) for bezuclastinib in …

… COSMIC-313 (NCT03937219) trial found that decreased kidney … , assistant professor of medicine, Harvard Medical School. Compared with patients … balanced between the 2 treatment arms, with a mean … in patients receiving sunitinib (Sutent). DISCLOSURES: Wenxin Xu …

… for Population Sciences, Harvard Medical School, Venkataraman shared insights … Yes! There are two trials that I think are … Sutent is conventionally the second-line treatment in that population. This trial … are some phase 1 trials looking at the combination …

… Medical School. Can you discuss emerging second- and third-line treatment … of a large multicenter trial looking at Sutent (sunitinib) versus IDRX … second and third line of treatment. So those are the … there are some phase 1 trials looking at the combination of …

… there are now several trials have supported the use … Medicine, moderated a discussion on how to select treatment … several TKIs, including sunitinib [Sutent], cabozantinib, and lenvatinib [Lenvima … Lobins, DO: The SUNNIFORECAST trial [NCT03075423] mirrors the …

… of Internal Medicine at Mayo Clinic, discusses the CABINET trial (NCT03375320) … months set by sunitinib (Sutent), another TKI approved in … [treatment], if you will, and was approved by the FDA for … the [Alliance for Clinical Trials in Oncology]. Dr Jennifer …